Angela Luise H.
- Country
- Germany
- Department
- Medizinische Klinik I
Research Overview
- Randomized Phase 3 Trial of Telisotuzumab adizutecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer
- Phase 2 Multicenter Study of Rituximab, Polatuzumab Vedotin, and Glofitamab in Untreated Aggressive B-cell Lymphoma Patients Aged >60 Ineligible for R-CHOP
- Phase III Trial on Preoperative Chemotherapy with Irinotecan, Oxaliplatin, and Capecitabine in Resectable Advanced Colon Cancer
Data & Insights
Has run more than one trial at 22 of 211 partner sites.
Specializations
Lymphoma Research
This investigator specializes in the treatment of aggressive B-cell lymphoma and follicular lymphoma, with particular emphasis on developing innovative therapeutic approaches for previously untreated patients.
- Chemotherapy-light combinations
- Novel antibody-based therapies
- Age-specific treatment strategies
Their research focuses on evaluating alternative treatment options for patients who cannot receive standard therapeutic regimens.
Colorectal Oncology
The investigator conducts research in advanced colon cancer treatment, specifically examining preoperative therapeutic approaches for resectable cases.
- Preoperative systemic therapy
- Surgical timing optimization
- Stage-guided treatment protocols
Their work encompasses the evaluation of treatment sequencing in locally advanced colon cancer management.
Therapeutic Innovation
The investigator explores combination therapy approaches in hematologic malignancies, particularly focusing on integrating novel therapeutic agents.
- Monoclonal antibody applications
- Immunotherapy combinations
- Progressive treatment strategies
Their research aims to establish more effective treatment protocols for specific patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.